Understanding these flops might reveal systematic trends and biases within the Review itself. Is there a consistent overestimation of the scalability of drugs that have gone through successful initial trials? Is the Review prone to being influenced by media hype cycles? Is there a bias towards picking technologies that will impact the demographics of readers of the Review more than they will the rest of the global population?